BioSyent Inc. (CVE:RX) Senior Officer Robert Joseph March Sells 4,775 Shares

BioSyent Inc. (CVE:RX) Senior Officer Robert Joseph March sold 4,775 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75.

BioSyent Trading Up 3.2 %

Shares of BioSyent stock opened at C$11.98 on Friday. The company’s fifty day moving average is C$11.21 and its two-hundred day moving average is C$10.54. BioSyent Inc. has a 1 year low of C$8.24 and a 1 year high of C$11.98. The company has a debt-to-equity ratio of 3.19, a quick ratio of 6.91 and a current ratio of 6.13. The company has a market capitalization of C$138.85 million, a P/E ratio of 19.97 and a beta of 0.93.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.